Overview

Efficacy of Low-dose Interleukin-2 Treatment in Chronic Spontaneous Urticaria

Status:
Not yet recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, controlled, single-center clinical study to evaluate the short-term efficacy of low-dose Interleukin-2 injection as an add-on therapy for the treatment of patients aged 18-75 who have been diagnosed with CSU and remain symptomatic despite oral antihistamine treatment .
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Second Xiangya Hospital of Central South University
Treatments:
Aldesleukin
Interleukin-2